We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+50.91%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$388M
AUM Growth
-$19.7M
Cap. Flow
-$118M
Cap. Flow %
-30.34%
Top 10 Hldgs %
28.14%
Holding
181
New
33
Increased
26
Reduced
86
Closed
36

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$6.38M
2
MAZE
Maze Therapeutics
MAZE
+$5.85M
3
TERN
Terns Pharmaceuticals
TERN
+$4.05M
4
PHVS icon
Pharvaris
PHVS
+$3.91M
5
STOK icon
Stoke Therapeutics
STOK
+$3.47M

Top Sells

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$12.9M
2
MRUS
Merus
MRUS
+$12.6M
3
ABVX
Abivax
ABVX
+$12.3M
4
SNDK
Sandisk
SNDK
+$8.63M
5
DBC icon
Invesco DB Commodity Index Tracking Fund
DBC
+$8.61M

Sector Composition

Rank Sector Weight
1 Healthcare 69.79%
2 Technology 6.85%
3 Industrials 5.94%
4 Financials 3.09%
5 Consumer Discretionary 2.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BABA icon
151
Alibaba
BABA
$306B
– –
-3,757
Closed -$671K
BAC icon
152
Bank of America
BAC
$448B
– –
-27,500
Closed -$1.42M
BEKE icon
153
KE Holdings
BEKE
$18.7B
– –
-11,400
Closed -$217K
CNM icon
154
Core & Main
CNM
$8.73B
– –
-27,900
Closed -$1.5M
COF icon
155
Capital One
COF
$134B
– –
-9,674
Closed -$2.06M
CRBP icon
156
Corbus Pharmaceuticals
CRBP
$184M
– –
-118,027
Closed -$1.49M
CRH icon
157
CRH
CRH
$67.4B
– –
-19,439
Closed -$2.33M
CSCO icon
158
Cisco
CSCO
$475B
– –
-21,800
Closed -$1.49M
CZR icon
159
Caesars Entertainment
CZR
$6.06B
– –
-43,000
Closed -$1.16M
DVAX
160
DELISTED
Dynavax Technologies
DVAX
– –
-192,849
Closed -$1.91M
ENTG icon
161
Entegris
ENTG
$23B
– –
-15,700
Closed -$1.45M
EOLS icon
162
Evolus
EOLS
$551M
– –
-226,025
Closed -$1.39M
FN icon
163
Fabrinet
FN
$18.8B
– –
-5,100
Closed -$1.86M
INBX icon
164
Inhibrx
INBX
$1.36B
– –
-7,626
Closed -$257K
JCI icon
165
Johnson Controls International
JCI
$93.7B
– –
-11,100
Closed -$1.22M
KROS icon
166
Keros Therapeutics
KROS
$211M
– –
-83,050
Closed -$1.31M
MLTX icon
167
MoonLake Immunotherapeutics
MLTX
$1.41B
– –
-19,059
Closed -$137K
MRUS
168
DELISTED
Merus
MRUS
– –
-133,321
Closed -$12.6M
NTRA icon
169
Natera
NTRA
$45.1B
– –
-6,580
Closed -$1.06M
PGR icon
170
Progressive
PGR
$123B
– –
-5,500
Closed -$1.36M
PWR icon
171
Quanta Services
PWR
$101B
– –
-5,200
Closed -$2.15M
ROIV icon
172
Roivant Sciences
ROIV
$25.5B
– –
-98,858
Closed -$1.5M
SRRK icon
173
Scholar Rock
SRRK
$6.34B
– –
-59,573
Closed -$2.22M
STX icon
174
Seagate
STX
$186B
– –
-6,898
Closed -$1.63M
TAL icon
175
TAL Education Group
TAL
$6.75B
– –
-19,600
Closed -$220K
4 5 6
7
8

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
PPG
Peak Planning Group Centennial, Colorado $361M AUM 22.01% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

HighVista Strategies's Q4 2025 Portfolio in Review

As of Q4 2025, HighVista Strategies held 181 positions worth $388M, down 4.8% from $408M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

HighVista Strategies withdrew a net $118M in Q4 2025, closing 36 positions and reducing 86 holdings. Its most notable exit was Merus, an estimated $12.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 59% a quarter earlier, followed by Technology and Industrials.

Against the trend, HighVista Strategies opened a new position in Maze Therapeutics worth $7.06M.

  • HighVista Strategies's largest Q4 2025 buy was Maze Therapeutics: 170,353 shares worth $7.06M.
  • HighVista Strategies added most to Soleno Therapeutics in Q4 2025, an estimated $6.38M increase.
  • HighVista Strategies's biggest Q4 2025 reduction was Praxis Precision Medicines, cutting an estimated $12.9M.
  • HighVista Strategies fully exited Merus in Q4 2025, selling an estimated $12.6M.
  • HighVista Strategies's ten largest holdings make up 28% of its $388M portfolio in Q4 2025.
  • HighVista Strategies opened 33 new positions and closed 36 in Q4 2025.
  • HighVista Strategies's portfolio value fell 4.8% quarter-over-quarter to $388M.

Based on HighVista Strategies's 13F filing for Q4 2025, filed 17 Feb 2026.